Rotenone induces gastrointestinal pathology and microbiota alterations in a rat model of Parkinson’s disease

Posted by: | March 5, 2018 | Comments

ABSTRACT

While people are often aware of the motor symptoms in Parkinson’s disease (PD), few know of the many non-motor symptoms, which patients report have a greater impact on their quality of life. Gastrointestinal (GI) dysfunction is one of the most common non-motor symptoms, which can occur at any stage of PD, even years prior to diagnosis, and can affect all sections along the GI tract causing a range of symptoms including drooling, gastroparesis and constipation. We have investigated whether a neurotoxin model of PD- rotenone, a mitochondrial complex I inhibitor, is capable of reproducing the GI dysfunction seen clinically. Sprague-Dawley rats were administered 2.75 mg/kg rotenone, 5 days/week for 4 weeks, via intraperitoneal injection.

Read more at: ScienceDirect

Michaela E.Johnson, Andrea Stringer, Larisa Bobrovskaya. DOI: https://doi.org/10.1016/j.neuro.2018.02.013. 20 February 2018.





Stay up-to-date!
Email Address *
First Name
Last Name

* indicates required
Privacy Policy




Terms & Conditions | Privacy Policy | © 2018 The Translational Microbiome Research Forum